MA56430B1 - Composés de benzothiadiazépine et leur utilisation en tant que modulateurs d'acide biliaire - Google Patents
Composés de benzothiadiazépine et leur utilisation en tant que modulateurs d'acide biliaireInfo
- Publication number
- MA56430B1 MA56430B1 MA56430A MA56430A MA56430B1 MA 56430 B1 MA56430 B1 MA 56430B1 MA 56430 A MA56430 A MA 56430A MA 56430 A MA56430 A MA 56430A MA 56430 B1 MA56430 B1 MA 56430B1
- Authority
- MA
- Morocco
- Prior art keywords
- bile acid
- compounds
- acid modulators
- benzothiadiazepine
- relates
- Prior art date
Links
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title abstract 3
- 239000003613 bile acid Substances 0.000 title abstract 3
- KAOYLRLQZXRRBD-UHFFFAOYSA-N 1,2,3-benzothiadiazepine Chemical class S1N=NC=CC2=CC=CC=C12 KAOYLRLQZXRRBD-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- CICPSCXBPAGDJY-UHFFFAOYSA-N 1,2,5-benzothiadiazepine Chemical class S1N=CC=NC2=CC=CC=C12 CICPSCXBPAGDJY-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 abstract 1
- 108091006614 SLC10A2 Proteins 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 230000004129 fatty acid metabolism Effects 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des dérivés de 1, 2, 5-benzothiadiazépine de formule (i). Ces composés sont des modulateurs d'acide biliaire ayant une activité inhibitrice de transporteur d'acide biliaire dépendant du sodium apical (asbt) et/ou de transport d'acide biliaire hépatique (lbat). L'invention concerne également des compositions pharmaceutiques comprenant ces composés et l'utilisation de ces composés dans le traitement de maladies cardiovasculaires, de troubles du métabolisme des acides gras et du glucose, de maladies gastro-intestinales et de maladies hépatiques.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201911004690 | 2019-02-06 | ||
| PCT/EP2020/052942 WO2020161217A1 (fr) | 2019-02-06 | 2020-02-06 | Composés de benzothiadiazépine et leur utilisation en tant que modulateurs d'acide biliaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA56430A MA56430A (fr) | 2022-05-11 |
| MA56430B1 true MA56430B1 (fr) | 2023-01-31 |
Family
ID=78076066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA56430A MA56430B1 (fr) | 2019-02-06 | 2020-02-06 | Composés de benzothiadiazépine et leur utilisation en tant que modulateurs d'acide biliaire |
Country Status (2)
| Country | Link |
|---|---|
| AR (2) | AR118026A1 (fr) |
| MA (1) | MA56430B1 (fr) |
-
2020
- 2020-02-06 AR ARP200100329A patent/AR118026A1/es unknown
- 2020-02-06 AR ARP200100328A patent/AR118025A1/es unknown
- 2020-02-06 MA MA56430A patent/MA56430B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR118026A1 (es) | 2021-09-15 |
| MA56430A (fr) | 2022-05-11 |
| AR118025A1 (es) | 2021-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521422625B1 (ar) | مركبات بنزوثيادايازيبين واستخدامها كمعدلات لحمض الصفراء | |
| SA522432741B1 (ar) | مركبات بنزوثيا (داي) أزيبين واستخدامها كمعدِّلات للأحماض الصفراوية | |
| ZA202400117B (en) | Benzothia(di)azepine compounds and their use as bile acid modulators | |
| CL2022001453A1 (es) | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar | |
| BR112023010799A2 (pt) | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares | |
| MA34898B1 (fr) | Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques | |
| MA32108B1 (fr) | Derives d'indazole | |
| MA34400B1 (fr) | Dérivés d'acide 2-quinolinyl-acétique en tant que composés antiviraux contre le vih | |
| EA201270666A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
| MA33083B1 (fr) | Nouveaux lipides contenant du soufre pour utilisation en tant que supplément alimentaire ou médicament | |
| MA31919B1 (fr) | Composés inhibiteurs de la dipeptidyl peptidase-iv, leurs procédés de préparation, et compositions pharmaceutiques contenant ces composés comme agent actif | |
| MA35750B1 (fr) | Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c) | |
| MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
| MA33239B1 (fr) | 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires | |
| MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
| MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
| MA46342B1 (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
| MA38694B1 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
| WO2018224736A3 (fr) | Dérivés stéroïdiens thérapeutiquement actifs | |
| MA47082B1 (fr) | Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1 | |
| MA29793B1 (fr) | Derives d'imidazole pour le traitement de troubles neurologiques. | |
| FR2869904A1 (fr) | Modulateurs des recepteurs lxr | |
| MA29329B1 (fr) | Derives d'amide en tant que ligands de canal ionique, compositions pharmaceutiques et methodes d'utilisation associees | |
| MA30267B1 (fr) | Derives amides en tant que ligands de canal ionique et compositions pharmaceutiques et procedes d'utilisation de tels derives | |
| MA53135B1 (fr) | Composés de c-mannoside utiles pour le traitement d'infections des voies urinaires |